Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Acquires N-of-One to Add Molecular Decision Support

NEW YORK (GenomeWeb) – Qiagen said today that it has acquired molecular oncology decision company N-of-One. Terms were not disclosed, but Qiagen said it made the purchase with cash reserves.

In purchasing Concord, Massachusetts-based N-of-One, Qiagen expects to beef up its offerings in decision support and offer its customers better clinical interpretation technologies for genomic data in pursuit of new, targeted therapies.

N-of-One has built a proprietary somatic cancer database called MarkerMine, which now contains more than 125,000 patient samples. Its technology helps pathologists create reports for clinicians that include genetic variant interpretation, DNA change, effect, and causative condition.

"N-of-One has made tremendous strides in molecular oncology decision support, and their combination with Qiagen's own pre-curated knowledge base of evidence will provide powerful new tools to expand our abilities to deliver patient-specific insights,” Qiagen Senior Vice President for Bioinformatics Jonathan Sheldon said in a statement.

Qiagen, based in Hilden, Germany, said that it expects to integrate N-of-One's MarkerMine database into its own Qiagen Clinical Insight software for analysis and interpretation of next-generation sequencing.